Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0035412 (rhabdomyosarcoma)
 6,156 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

B cells producing antibodies against the acetylcholine receptor (AchR) play a central role in the pathogenesis of myasthenia gravis (MG). Although anti-AchR autoantibodies have been studied extensively, not much is known about autoimmune B cells and their antigen-driven activation. This has mainly been due to difficulties in establishing and maintaining untransformed antigen-specific B cells in vitro. In this study, we show that highly enriched B cells from peripheral blood and thymus of MG patients can be maintained in culture over a period of 4 weeks when grown on the AchR-expressing rhabdomyosarcoma cell line TE671 together with an anti-CD40 stimulus and lymphokines. Anti-AchR antibody secretion could be detected in the majority of B cell cultures on TE671 cells up to 4 weeks. In contrast, B cells cultured on CDw32-transfected L cells binding anti-CD40 antibodies (the CD40 system) produced only small amounts of anti-AchR antibodies at single time points, whereas the overall IgG production was higher than on TE671 cells. The expression of the relevant autoantigen on the adherent cell line in addition to other growth stimuli could account for this difference and may provide a useful tool for investigating antigen-dependent B cell activation in MG and other B cell-mediated autoimmune conditions.
 ...
PMID:Myasthenia gravis: selective enrichment of antiacetylcholine receptor antibody production in untransformed human B cell cultures. 1055 8

In present work the role of tumor cell biology upon different conditions of their interaction with the cells of immune system is discussed. The presented data show that it tumor cell biology that in many cases determines tumor antigen recognition and realization of cytotoxic action of killer cells. Here also we discuss own data obtained with the use of experimental tumor models (transplantable MC-rhabdomyosarcoma, B16 melanoma) and human tumors (soft tissue sarcoma, melanoma, breast cancer, ovarian cancer, cervical cancer). It was demonstrated that various tumors have different sensitivity to antitumor action of activated (LAK) and non-activated lymphocytes. Recent studies on the role of tumor cells in expansion and activity of different suppressor cells (MDSC, Treg, Th17, M-2 macrophages, etc.) are overviewed. The role of organ-specificity and interaction of the components of microenvironment (cells of immune system and stroma, tumor cells, endothelial cells, extracellular matrix) are discussed in details. Along with the presentation of modern views on some patterns that characterize the development of drug resistance of different tumors and capabilities of immune system cells to participate in lysis of resistant tumor cells, the authors present their own data illustrating that resistant tumor cells reveal increased sensitivity to LAK. An analysis of the involvement of a number of molecules, lymphocytes, and tumor cells in the phenomenon of elevated sensitivity to LAK action allowed to conclude that tumor cells reveal high sensitivity at the background of decreased E-cadherin expression and increased CD40 expression.
 ...
PMID:Interaction between tumor and immune system: the role of tumor cell biology. 2140 11